Almirall SA
OTC:LBTSF

Watchlist Manager
Almirall SA Logo
Almirall SA
OTC:LBTSF
Watchlist
Price: 15.47 USD Market Closed
Market Cap: 3.3B USD

Net Margin

3.5%
Current
Improving
by 3.8%
vs 3-y average of -0.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.5%
=
Net Income
€55.5m
/
Revenue
€1.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.5%
=
Net Income
$55.5m
/
Revenue
€1.6B

Peer Comparison

Country Company Market Cap Net
Margin
ES
Almirall SA
MAD:ALM
2.8B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
213.9B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Spain
Percentile
34rd
Based on 645 companies
34rd percentile
3.5%
Low
-9 204.1% — 2.1%
Typical Range
2.1% — 19.8%
High
19.8% — 603.4%
Distribution Statistics
Spain
Min -9 204.1%
30th Percentile 2.1%
Median 10.5%
70th Percentile 19.8%
Max 603.4%

Almirall SA
Glance View

Market Cap
3.3B USD
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

LBTSF Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
3.5%
=
Net Income
€55.5m
/
Revenue
€1.6B
What is Almirall SA's current Net Margin?

The current Net Margin for Almirall SA is 3.5%, which is above its 3-year median of -0.3%.

How has Net Margin changed over time?

Over the last 3 years, Almirall SA’s Net Margin has increased from 2.7% to 3.5%. During this period, it reached a low of -4.3% on Dec 31, 2023 and a high of 3.5% on Oct 30, 2025.

Back to Top